Chronic myeloid leukemia: A minimalistic view of post-therapeutic monitoring

Journal of Molecular Diagnostics

Volumn 4, Issue 1, 2002, Pages 1-10

  Bagg, Adam ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASE; INTERFERON; MESSENGER RNA; RNA;

CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC ANALYSIS; HEMATOLOGIC DISEASE; HUMAN; MINIMAL RESIDUAL DISEASE; NEPHROBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; DRUG MONITORING; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; SENSITIVITY AND SPECIFICITY;

DRUG MONITORING; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY;

EID: 0036484238     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-1578(10)60675-7     Document Type: Review

References (74)

1. Bagg A: Minimal residual disease: how low do we go? Mol Diagn 2001, 6:155-160
2. Foroni L, Harrison CJ, Hoffbrand AV, Potter MN: Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol 1999, 105:7-24
3. Campana D, Neale GA, Coustan-Smith E, Pui CH: Detection of minimal residual disease in acute lymphoblastic leukemia: the St. Jude experience. Leukemia 2001, 15:278-279
4. Faderl S, Talpaz M, Kantarjian HM, Estrov Z: Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 1999, 93:2755-2759
5. Roman J, Alvarez MA, Torres A: Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000, 85:1072-1082
6. Hochhaus A, Weisser A, La Rosee P, Emig M, Muller MC, Saussele S, Reiter A, Kuhn C, Berger U, Hehlmann R, Cross NC: Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000, 14:998-1005
7. Virchow R: Weisses Blut. Floriep's Notizen 1845, 36:151-156
8. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497
9. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293
10. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G: Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983, 306:239-242
11. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830
12. Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356
13. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037
14. Mintzer DA, Bagg A: Clinical syndromes of transformation in clonal hematologic disorders. Am J Med 2001, 111:480-488
15. Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G, Nwachukwu B, Kim P, Guo J, Kamel-Reid S: Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol 1998, 103:711-715
16. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S: An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999, 94:1517-1536
17. Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001, 7:228-234
18. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880
19. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med 1991, 114:532-538
20. Waller CF, Dennebaum G, Feldmann C, Lange W: Long-template DNA polymerase chain reaction for the detection of the bcr/abl translocation in patients with chronic myelogenous leukemia. Clin Cancer Res 1999, 5:4146-4151
21. Wang YL, Bagg A, Pear W, Nowell PC, Hess JL: Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer 2001, 32:97-111
22. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995, 86:3118-3122
23. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92:3362-3367
24. Holyoake T, Jiang X, Eaves C, Eaves A: Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056-2064
25. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner K: Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995, 86:2371-2378
26. Corsetti MT, Lerma E, Dejana A, Basta P, Ferrara R, Benvenuto F, Vassallo F, Abate M, Piaggio G, Parodi C, Sessarego M, Li Pira G, Manca F, Carella AM: Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia. Leukemia 1999, 13:999-1008
27. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM: Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6:1018-1023
28. Goldman JM, Kaeda JS, Cross NC, Hochhaus A, Hehlmann R: Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease. Blood 1999, 94:1484-1486
29. Lion T: Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood 1999, 94:1486-1488
30. Moravcova J, Nadvormkova S, Lukasova M, Klamova H: Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia. Blood 1999, 94:3609-3611
31. Lion T: Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clinical aspects. Leukemia 1996, 10:896-900; 901-906
32. Morgan GJ, Hughes T, Janssen JW, Gow J, Quo AP, Goldman JM, Wiedemann LM, Bartram CR: Polymerase chain reaction for detection of residual leukaemia. Lancet 1989, 1:928-929
33. Hughes T, Janssen JW, Morgan G, Martial P, Saglio G, Pignon JM, Pignatti FP, Mills K, Keating A, Gluckman E: False-positive results with PCR to detect leukaemia-specific transcript. Lancet 1990, 335:1037-1038
34. Hughes T, Goldman JM: Improved results with PCR for chronic myeloid leukaemia. Lancet 1990, 336:812
35. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993, 82:1929-1936
36. Hughes TP, Morgan GJ, Martiat P, Goldman JM: Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991, 77:874-878
37. Roth MS, Antin JH, Ash R, Terry VH, Gotlieb M, Silver SM, Ginsburg D: Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992, 79:276-282
38. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR, Thomas ED: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632-2638
39. Miyamura K, Tahara T, Tanimoto M, Morishita Y, Kawashima K, Morishima Y, Saito H, Tsuzuki S, Takeyama K, Kodera Y: Long persistent bcr-abl-positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood 1993, 81:1089-1093
40. Gaiger A, Lion T, Kalhs P, Mitterbauer G, Henn T, Haas O, Fodinger M, Kier P, Forstinger C, Quehenberger P: Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT). Leukemia 1993, 7:1766-1772
41. Serrano J, Roman J, Sanchez J, Jimenez A, Castillejo JA, Herrera C, Gonzalez MG, Reina L, Rodriguez MC, Alvarez MA, Maldonado J, Torres A: Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. Blood 2000, 95:2659-2665
42. Lin F, van Rhee F, Goldman JM, Cross NC: Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996, 87:4473-4478
43. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NC, Goldman JM: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565
44. Drobyski WR, Endean DJ, Klein JP, Hessner MJ: Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. Br J Haematol 1997, 98:458-466
45. Raanani P, Dazzi F, Sohal J, Szydlo RM, van Rhee F, Reiter A, Lin F, Goldman JM, Cross NC: The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997, 99:945-950
46. Formankova R, Honzatkova L, Moravcova J, Sieglova Z, Dvorakova R, Nadvornikova S, Vitek A, Lukasova M, Stary J, Brdicka R: Prediction and reversion of post-transplant relapse in patients with chronic myeloid leukemia using mixed chimerism and residual disease detection and adoptive immunotherapy. Leuk Res 2000, 24:339-347
47. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M: Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998, 16:1526-1531
48. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000, 95:62-66
49. Martinelli G, Testoni N, Amabile M, Bonifazi F, De Vivo A, Farabegoli P, Terragna C, Montefusco V, Ottaviani E, Saglio G, Russo D, Baccarani M, Rosti G, Tura S: Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy. Bone Marrow Transplant 2000, 25:729-736
50. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996, 87:1549-1555
51. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R: Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia: analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994, 94:1383-1389
52. Chomel JC, Brizard F, Veinstein A, Rivet J, Sadoun A, Kitzis A, Guilhot F, Brizard A: Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000, 95:404-408
53. Pane F, Mostarda I, Selleri C, Salzano R, Raiola AM, Luciano L, Saglio G, Rotoli B, Salvatore F: BCR/ABL mRNA and the P210(BCR/ABL) protein are down-modulated by interferon-alpha in chronic myeloid leukemia patients. Blood 1999, 94:2200-2207
54. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ: The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997, 22:176-181
55. Holland PM, Abramson RD, Watson R, Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991, 88:7276-7280
56. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999, 13:1825-1832
57. Kreuzer KA, Lass U, Bohn A, Landt O, Schmidt CA: LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 1999, 59:3171-3174
58. Bolufer P, Sanz GF, Barragan E, Sanz MA, Cervera J, Lerma E, Senent L, Moreno I, Flanelles MD: Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes. Haematologica 2000, 85:1248-1254
59. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T: Quantitation of minimal residual disease in Philadelphia chromosome-positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998, 102:768-774
60. Branford S, Hughes TP, Rudzki Z: Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999, 107:587-599
61. Preudhomme C, Revillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, Jouet JP, Cosson A, Peyrat JP, Fenaux P: Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a "real time" quantitative RT-PCR assay. Leukemia 1999, 13:957-964
62. Saffroy R, Lemoine A, Brezillon P, Frenoy N, Delmas B, Goldschmidt E, Souleau B, Nedellec JG, Debuire B: Real-time quantitation of bcr-abl transcripts in haematological malignancies. Eur J Haematol 2000, 65:258-266
63. Amabile M, Giannini B, Testoni N, Montefusco V, Rosti G, Zardini C, Terragna C, Buonamici S, Ottaviani E, Soverini S, Fiacchini M, Bassi S, de Vivo A, Trabacchi E, Saglio G, Pane F, Baccarani M, Tura S, Martinelli G: Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica 2001, 86:252-259
64. Elmaagacli AH, Freist A, Hahn M, Opalka B, Seeber S, Schaefer UW, Beelen DW: Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method. Br J Haematol 2001, 113:1072-1075
65. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW: The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome-positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol 2000, 79:424-431
66. Zanella I, Rossi G, Finazzi D, Capucci A, Albertini A, Cariani E: Quantification of bcr/abl mRNA expression by a rapid real-time reverse transcription-polymerase chain reaction assay in patients with chronic myeloid leukemia. Haematologica 2001, 86:318-319
67. Lion T, Gaiger A, Henn T, Horth E, Haas OA, Geissler K, Gadner H: Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 1995, 9:1353-1360
68. Lion T: Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia: The European Investigators on Chronic Myeloid Leukemia Group. Bone Marrow Transplant 1994, 14:505-509
69. Martinelli G, Montefusco V, Testoni N, Amabile M, Saglio G, Ottaviani E, Terragna C, Bonifazi F, Rosti G, Bandini G, Tura S: Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000, 85:653-658
70. Burmeister T, Maurer J, Aivado M, Elmaagacli AH, Grunebach F, Held KR, Hess G, Hochhaus A, Hoppner W, Lentes KU, Lubbert M, Schafer KL, Schafhausen P, Schmidt CA, Schuler F, Seeger K, Seelig R, Thiede C, Viehmann S, Weber C, Wilhelm S, Christmann A, Clement JH, Ebener U, Enczmann J, Leo R, Schleuning M, Schoch R, Thiel E: Quality assurance in RT-PCR-based BCR/ABL diagnostics: results of an interlaboratory test and a standardization approach. Leukemia 2000, 14:1850-1856
71. Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M: Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. Leukemia 1992, 6:754-760
72. Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen AC, Landegren U: Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 2000, 46:913-920
73. Silva NH, Pimenta G, Pulcheri WA, Fournier MV, Spector N, da Costa Carvalho MG: Detection of messenger RNA in leukocytes or plasma of patients with chronic myeloid leukemia. Oncol Rep 2001, 8:693-696
74. Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M: Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification. Br J Haematol 2001, 112:749-759